Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s ...
Arvinas and Pfizer are the first to take a PROteolysis TArgeting Chimera (PROTAC) therapy across the FDA finish line, opening ...
By Mariam Sunny and Christy Santhosh May 5 (Reuters) - Pfizer reported higher-than-expected sales and profit on Tuesday and ...
The FDA has approved Pfizer and Arvinas’ Veppanu, the first proteolysis-targeting chimera (PROTAC) therapy, for advanced ER-positive, HER2-negative breast cancer with ESR1 mutations after prior ...
VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader –– Approval received in advance of ...
Revenue reached $14.45 billion, up 5% year-over-year, as oncology and other recently launched products offset steep declines ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Guardant360® CDx liquid biopsy test as a ...
Pfizer and Arvinas are poised to bring the third oral selective oestrogen receptor degrader (SERD) to market in the US, after ...
If the crackdown on pharma’s TV ads and subsequent extension to social media has underscored anything, it’s that brands need ...
Pfizer’s $2.3 billion bet on Trillium Therapeutics doesn’t look like it will ever pay out, with the Big Pharma abandoning the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results